Patents Assigned to Fusion Antibodies Limited
-
Patent number: 9321838Abstract: The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumor cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.Type: GrantFiled: April 10, 2007Date of Patent: April 26, 2016Assignee: Fusion Antibodies LimitedInventors: Shane Olwill, Christopher Scott, Julie Gormley, Jaquin Thomas, Roberta Burden, Darragh McMeel, James Johnston
-
Patent number: 8846868Abstract: Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.Type: GrantFiled: April 17, 2009Date of Patent: September 30, 2014Assignee: Fusion Antibodies LimitedInventors: Jill Caswell, Shane Olwill, James Johnston, Richard Buick, Thomas Jaquin, Declan Doherty, Christopher Scott
-
Patent number: 8747849Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.Type: GrantFiled: March 18, 2011Date of Patent: June 10, 2014Assignee: Fusion Antibodies LimitedInventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
-
Patent number: 8475803Abstract: The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines.Type: GrantFiled: May 2, 2006Date of Patent: July 2, 2013Assignee: Fusion Antibodies LimitedInventors: Shane A. Olwill, Richard J. Buick, Hangfai Kwok, James A. Johnston
-
Publication number: 20110243955Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity.Type: ApplicationFiled: March 18, 2011Publication date: October 6, 2011Applicant: Fusion Antibodies LimitedInventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
-
Publication number: 20110150886Abstract: Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.Type: ApplicationFiled: April 17, 2009Publication date: June 23, 2011Applicant: FUSION ANTIBODIES LIMITEDInventors: Jill Caswell, Shane Olwill, James Johnston, Richard Buick, Thomas Jaquin, Declan Doherty, Christopher Scott
-
Patent number: 7939642Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.Type: GrantFiled: April 10, 2006Date of Patent: May 10, 2011Assignee: Fusion Antibodies LimitedInventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
-
Publication number: 20110020404Abstract: The invention relates to methods for diagnosis of tuberculosis in an animal, the methods comprising determining the presence or absence of, or an immune response to a group of antigens comprising (i) the group consisting of Rv3616 antigen, MPB70 antigen, MPB83 antigen, and ESAT 6 antigen; or (ii) at least seven of the antigens of the group consisting of Rv3616 antigen, MPB70 antigen, MPB83 antigen, ESAT 6 antigen, CFP10 antigen, ? crystalline 2 antigen, PE35 antigen, and PPE68 antigen. Also provided is a method for the diagnosis of the presence of tuberculosis in a reservoir animal e.g. a badger, said method comprising determining the presence or absence of, or an immune response to Rv3616 antigen, MPB70 antigen, and MPB83 antigen. Kits for carrying out the methods are also provided.Type: ApplicationFiled: August 18, 2008Publication date: January 27, 2011Applicants: FUSION ANTIBODIES LIMITED, ENFER TECHNOLOGY LIMITEDInventors: Shane A. Olwill, James A. Johnston, Hang Fai Kwok, Clare Whelan, John Clarke
-
Publication number: 20100111965Abstract: The invention provides a method of treating neoplastic disease in a subject, said method comprising the simultaneous, sequential or separate, administration to said subject of an effective amount of (i) an inhibitor of a first EGF, e.g. HB-EGF and (ii) an inhibitor of a second EGF, e.g. AREG. Also described are novel synergistic combinations of EGF inhibitors with topoisomerase inhibitors which attenuate tumour cell growth. Further described are novel anti AREG antibodies.Type: ApplicationFiled: October 11, 2007Publication date: May 6, 2010Applicant: FUSION ANTIBODIES LIMITEDInventors: James Johnston, Shane Olwill, Jill Brown, Nuala Morgan, Thomas Jaquin, Christopher Scott
-
Publication number: 20100104554Abstract: A method of inhibiting activity of a cathepsin L-like protease in cells or tissue and the use of the method in the treatment of disease such as cancer and inflammatory diseases is described. The method comprises administration of a cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide. In particular embodiments, the propeptide is a Cathepsin S propeptide. Further, the use of propeptides having an Fc portion is described.Type: ApplicationFiled: March 2, 2007Publication date: April 29, 2010Applicant: Fusion Antibodies Limited, a Corporation of Great BritianInventors: Christopher Scott, Roberta Burden, Jim Johnston, Mark McCurley, Philip Snoddy, Richard Buick
-
Publication number: 20100086551Abstract: A method of inhibiting angiogenesis in a group of cells, a tissue or an organ includes administering an antibody molecule or nucleic acid encoding an antibody molecule to the cells, tissue or organ, wherein the antibody molecule specifically binds cathepsin S, but does not inhibit proteolytic activity of cathepsin S.Type: ApplicationFiled: October 12, 2007Publication date: April 8, 2010Applicant: Fusion Antibodies LimitedInventors: Shane Olwill, Christopher Scott, James Johnston, Roberta Burden
-
Publication number: 20090317405Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.Type: ApplicationFiled: April 10, 2006Publication date: December 24, 2009Applicant: Fusion Antibodies LimitedInventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
-
Publication number: 20090269360Abstract: The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumour cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.Type: ApplicationFiled: April 10, 2007Publication date: October 29, 2009Applicant: Fusion Antibodies LimitedInventors: Shane Olwill, Christopher Scott, Julie Gormley, Jaquin Thomas, Roberta Burden, Darragh McMeel, James Johnston
-
Publication number: 20090053258Abstract: The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines.Type: ApplicationFiled: May 2, 2006Publication date: February 26, 2009Applicant: FUSION ANTIBODIES LIMITEDInventors: Shane A. Olwill, Richard J. Buick, Hangfai Kwok, James A. Johnston
-
Publication number: 20070286867Abstract: The invention provides combination therapies and methods for the treatment of cancers associates with p53 mutations. The method comprises the separate, sequential or simultaneous administration of a therapeutically effective amount of a) a specific binding member, for example CH-11, which binds to a cell death receptor, for example Fas, or a nucleic acid encoding said binding member and b) a chemotherapeutic agent, wherein the chemotherapeutic agent is a topoisomerase inhibitor, for example CPT-1 or a thymidylate synthase inhibitor, for example TDX. Synergistic cytotoxic effects have been demonstrated using such combinations.Type: ApplicationFiled: November 26, 2004Publication date: December 13, 2007Applicant: Fusion Antibodies LimitedInventors: Patrick Johnston, Daniel Longley
-
Publication number: 20070110761Abstract: Described is a novel purification tag, SNUT, based on the gene product of a sortase gene, in particular the srtA gene of Staphylococcus aureus and uses thereof. Also provided are expression constructs comprising DNA enoding the tag for the production of recombinant polypeptides. The tag can be used in methods of purifying soluble domains of a number of proteins previously not able to be isolated efficiently and methods of inducing and/or enhancing an immune response to an antigen of interest.Type: ApplicationFiled: December 29, 2003Publication date: May 17, 2007Applicant: Fusion Antibodies LimitedInventor: Christopher Scott
-
Publication number: 20060083738Abstract: The present invention provides a method of killing cancer cells and method of treatment of cancer comprising administration of a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent. The binding member pereferably binds to a Fas receptor. Also described are medicaments for use in treating cancer.Type: ApplicationFiled: May 16, 2003Publication date: April 20, 2006Applicant: FUSION ANTIBODIES LIMITEDInventors: Patrick Johnston, Daniel Longley